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Massive parallel sequencing uncovers actionable
FGFR2–PPHLN1 fusion and ARAF mutations in
intrahepatic cholangiocarcinoma
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Intrahepatic cholangiocarcinoma (iCCA) is a fatal bile duct cancer with dismal prognosis and
limited therapeutic options. By performing RNA- and exome-sequencing analyses, we report
a novel fusion event, FGFR2–PPHLN1 (16%), and damaging mutations in the ARAF oncogene
(11%). Here we demonstrate that the chromosomal translocation t(10;12)(q26;q12) leading to
FGFR2–PPHLN1 fusion possesses transforming and oncogenic activity, which is successfully
inhibited by a selective FGFR2 inhibitor in vitro. Among the ARAFmutations, N217I and G322S
lead to activation of the pathway and N217I shows oncogenic potential in vitro. Screening
of a cohort of 107 iCCA patients reveals that FGFR2 fusions represent the most recurrent
targetable alteration (45%, 17/107), while they are rarely present in other primary liver
tumours (0/100 of hepatocellular carcinoma (HCC); 1/21 of mixed iCCA-HCC). Taken
together, around 70% of iCCA patients harbour at least one actionable molecular alteration
(FGFR2 fusions, IDH1/2, ARAF, KRAS, BRAF and FGF19) that is amenable for therapeutic
targeting.
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I
ntrahepatic cholangiocarcinoma (iCCA) is an aggressive
malignancy with a 5-year survival rate less than 10% (ref. 1).
Surgery is the only curative option for iCCA, although it is
limited to patients with early-stage disease2. The majority of
iCCA patients are diagnosed at more advanced stages, where
there is no accepted standard of care2,3. Therefore, there is an
unmet need to develop a ﬁrst-line therapy for these patients2.
A deeper knowledge of the molecular mechanisms underlying
this disease is crucial for the development of new effective
targeted therapies. Of late, there has been a signiﬁcant
improvement in our understanding of the molecular basis of
iCCA4. Large-scale molecular proﬁling studies have enabled the
ﬁrst molecular classiﬁcations to emerge5,6. Furthermore, deep-
sequencing studies have provided a preliminary description of
somatic mutations for iCCA7–10: novel mutations in chromatin
remodelling genes (BAP1, ARID1A and PBRM1) have been
recently unveiled, whereas frequent mutations in KRAS, IDH1
and IDH2 have been conﬁrmed8–11. Nonetheless, none of the
targetable mutations have been explored yet in early clinical trials.
In addition to somatic mutations, somatic gene fusions are able
to drive the development of human cancers, though their
translational relevance has been mostly limited to haematological
malignancies12. The recent discovery of novel fusion events
associated with different types of solid tumours, such as
prostate13, lung14 and breast15 cancer has increased the interest
in these genetic alterations. In fact, one of such fusions (the EML–
ALK fusion in lung cancer) has emerged as a druggable target and
its inhibition leads to survival improvements16. Interestingly, a
variety of FGFR2 gene fusions have been recently identiﬁed in
iCCA17–20, suggesting that these events may represent novel
candidate therapeutic targets and that similar strategies could be
used for its clinical management.
Massive parallel sequencing technology allows the character-
ization of cellular transcriptomes and genomes at single-base
resolution, including the detection of somatic gene mutations and
intragenic fusions that may lead to oncogenic molecular pathway
activation. To uncover candidate oncogenes that may represent
novel targets for iCCA therapy, we proﬁle a cohort of 122 iCCA
cases by performing RNA and DNA sequencing (discovery set:
seven and eight paired iCCA samples analysed, respectively;
screening cohort: 114 iCCA tissues). We discover a novel
recurrent oncogenic fusion gene, FGFR2–PPHLN1 (16%) and
damaging mutations in the oncogene ARAF (11%). The screening
of a large iCCA cohort reveals that around 70% of the tumours
harbour at least one targetable molecular alteration (for example,
FGFR2 fusions, KRAS/BRAF/EGFR/IDH mutations) with B45%
of patients analysed positive for at least one FGFR2 rearrange-
ment. Signiﬁcantly, the transforming and oncogenic activity of
the FGFR2–PPHLN1 fusion can be successfully inhibited by a
selective FGFR2 inhibitor (BGJ398) in vitro. Together our work
unveils a large fraction of iCCA patients with speciﬁc targetable
molecular alterations and reveals FGFR2 rearrangements as the
most recurrent molecular alteration event reported so far in this
disease.
Results
Identiﬁcation of a novel FGFR2 fusion event in iCCA. We
performed single-end RNA sequencing (RNA-seq) using high-
quality complementary DNA (cDNA) from seven tumour and
adjacent non-tumour liver tissues of resected human iCCA. By
applying stringent statistical criteria across the different steps of a
robust fusion identiﬁcation pipeline (see detailed online meth-
ods), we identiﬁed a total of 13 novel inter- and intrachromo-
somal fusion events (Supplementary Table 1). The best supported
(top ranked) fusion event was an interchromosomal fusion
comprising a portion of the tyrosine kinase receptor FGFR2 with
PPHLN1, a gene involved in epithelial differentiation. The
FGFR2–PPHLN1 was represented by 149 split reads harbouring
the fusion junction of exon 19 of FGFR2 to exon 4 of PPHLN1
(Supplementary Table 1) and was identiﬁed in one out of the
seven patients analysed (14.3%). Using primers spanning the
breakpoint, we conﬁrmed the fusion in the discovery tumour case
by reverse transcriptase-PCR (RT–PCR) and subsequent Sanger
sequencing of the PCR product (Fig. 1a,b). We then characterized
the complete sequence of the 50 FGFR2 fused to the 30 PPHLN1 by
performing broad-range PCR using primers spanning the starting
codon of FGFR2 and the 30untranslated region of PPHLN1
(Supplementary Fig. 1a, Supplementary Table 2). We veriﬁed that
the ﬁrst 19 exons of FGFR2 were present at the 50 end of the
fusion gene with an intact open reading frame and kinase
domains, suggesting its preserved kinase activity. At the 30 end,
the fusion partner PPHLN1 was missing only the ﬁrst three exons
of which the ﬁrst two are usually untranslated. Both partners have
been reported to exhibit tissue-speciﬁc splicing21. RNA-seq data
of the fusion case revealed that FGFR2IIIb isoform (Genbank
accession number NM-022970) and PPHLN1 isoform 3
(accession number NM_201439.1) were the most abundant
transcripts involved in the fusion protein (Supplementary
Fig. 1b).
In the normal genome, FGFR2 and PPHLN1 map to
chromosome 10q26 and 12q12, respectively, and are transcribed
in opposite directions. To verify the presence of a genomic DNA
rearrangement, we performed whole-genome sequencing (WGS)
of the tumour and matched non-tumour tissue where the fusion
was identiﬁed by RNA-seq. A translocation between chr10 and 12
was identiﬁed in the tumour and not in the corresponding non-
tumour tissue as the mechanism responsible for the fusion gene
FGFR2–PPHLN1 (Fig. 1c). These data allowed us to speciﬁcally
map the intronic junctions of the FGFR2–PPHLN1 fusion gene
and, using speciﬁc primers and subsequent Sanger sequencing, we
were able to annotate the sequence around the breakpoint
(Fig. 1c,d, Supplementary Table 3). The fusion was further
conﬁrmed by ﬂuorescent in situ hybridization (FISH) using two
speciﬁc probes for FGFR2 and PPHLN1 (Fig. 2a, upper panel). As
expected, the two probes co-localized only in the tumour tissue
with the fusion transcript.
To determine if this fusion gene is a recurrent event in iCCA
tumours, we screened 107 formalin-ﬁxed cases of iCCA by RT–
PCR and Sanger sequencing (screening cohort). Seventeen cases
(16%) were found positive for the presence of the fusion. In all
positive cases, the mRNA sequence around the breakpoint was
identical to the initial fusion (Fig. 2b). We then explored the
fusion event by using FISH in 10 cases of our screening cohort
(six negative and four positive patients) and obtained 90%
concordance between FISH and RT–PCR screening results
(Fig. 2a, lower panel). Together our screening identiﬁed a novel
FGFR2 fusion in iCCA, which accounts for 16% of the cohort
here analysed.
Transforming potential of FGFR2–PPHLN1. FGFR fusion
events have been recently identiﬁed in several cancers. Multiple
partners have been discovered including BICC1, AFF3, CASP7
and CCDC6 among others17–20. These different partners play an
important role in the control of enforced oligomerization and
subsequent trans-autophosphorylation and activation of the
tyrosine kinase gene involved in the rearrangement12,17,21. In
our case, the resulting protein (Fig. 3a) was predicted to contain
1111 amino acids (122 kDa) with the amino-terminal portion
(residues 1–768) identical to that of FGFR2, whereas the carboxy-
terminal portion (residues 769–1,111) was identical to PPHLN1
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7087
2 NATURE COMMUNICATIONS | 6:6087 | DOI: 10.1038/ncomms7087 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
starting at residue 25 of the wild-type (WT) protein
(Supplementary Fig. 1c). Interestingly, the C terminus domain
of the WT PPHLN1 protein could be responsible for
homodimerization22. To verify if PPHLN1 is able to mediate
dimerization and activation of the FGFR2 in the fusion gene, we
expressed V5-tagged FGFR2–PPHLN1 in 293T cells and
performed immunoprecipitation (Supplementary Fig. 2a). We
successfully demonstrated constitutive activation of the fusion
protein as indicated by the increased level of tyrosine
phosphorylation of the fusion kinase compared with the FGFR2
WT (Supplementary Fig. 2b, right panel) and activation of
downstream MAP kinase ERK1/2 (Supplementary Fig. 2c).
We then assessed the transforming potential of FGFR2–
PPHLN1 fusion protein reported herein. To this purpose,
NIH3T3 cells were stably transfected to overexpress V5-tagged
FGFR2–PPHLN1 and empty vector. As shown in Fig. 3b,c,
NIH3T3 cells expressing FGFR2–PPHLN1 showed anchorage-
independent colony formation in soft agar, which was completely
suppressed by the addition of the selective FGFR2 inhibitor
BGJ398 (1 mM) to the culture.
To further characterize the functional role of the identiﬁed
fusion in an iCCA in vitro model, we generated a stable HUCCT1
cell line overexpressing FGFR2–PPHLN1. Cells harbouring the
fusion presented increased viability, clonogenic and migratory
capacity (Supplementary Fig. 3a,b), suggesting an oncogenic
capability of the fusion protein. Furthermore, HUCCT1 cells
overexpressing the fusion protein showed an enhanced sensitivity
to BGJ398 compared with their parental cell line transfected with
the empty vector (Po0.001, Student’s t-test, Fig. 4a,b). In
particular, signiﬁcant inhibition of the migratory capability was
observed only in the cells expressing the fusion protein
(Po0.0001, Student’s t-test, Fig. 4b). The above ﬁndings support
the transforming and oncogenic potential of the FGFR2–
PPHLN1 fusion protein and the possible efﬁcacy of FGFR2
inhibitors in the clinical management of iCCA patients harbour-
ing FGFR2 rearrangements.
FGFR2 fusions are the most recurrent molecular alterations. To
elucidate the prevalence of FGFR2 fusion events in iCCA, we also
screened our large iCCA cohort (screening set) for the presence of
the FGFR2–BICC1 fusion17. This screening revealed that 38%
(40/107) of the analysed tumours harboured the FGFR2–BICC1
fusion transcript (Fig. 4c). Interestingly, FGFR2 fusions (FGFR2–
PPHLN1 and FGFR2–BICC1) were not mutually exclusive and
overall 45% of iCCA patients (48/107) harboured at least one
FGFR2 fusion. FGFR2 fusions were not detected in a set of 100
hepatocellular carcinomas (HCCs) and were very rare in mixed
HCC–iCCA cancers, with only one case out of 21 patients
analysed (5%) harbouring a FGFR2–BICC1 fusion gene (Fig. 4c).
No signiﬁcant association of the FGFR2 fusions was found
with clinico-pathological parameters or outcome (Supplementary
Table 4).
Single-sample gene set enrichment analysis (ssGSEA) in
genome-wide transcriptome proﬁles of 107 tumours of the
screening set revealed a signiﬁcant enrichment of genes in the
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Figure 1 | Transcriptome analysis identiﬁed a novel FGFR2–PPHLN1 fusion event. (a) RT–PCR of all seven paired tumour/normal cases using primers
spanning the breakpoint conﬁrmed the presence of a band only in the index case and not in its normal counterpart. (b) Schematic representation of the
identiﬁed mRNA fusion gene. FGFR2–PPHLN1 fusion mRNA is represented. Sanger sequencing conﬁrmed the chimeric junction between FGFR2 and PPHLN1
(arrows indicate the position of the primers used for RT–PCR and Sanger sequencing). (c) FGFR2 and PPHLN1 genes map to 10q26 and 12q12, respectively.
These genes are normally transcribed in opposite directions. WGS of the tumoral case and matched normal tissue where the FGFR2 fusion was identiﬁed
conﬁrmed the presence of a translocation t(10;12)(q26;q12) as responsible mechanism for the generation of the chimeric fusion gene. Circle plot for this
translocation is represented. (d) Schematic representation of the translocation responsible for the generation of a FGFR2–PPHLN1 in frame event. PCR on
the DNA and subsequent Sanger sequencing conﬁrmed the exact breakpoint in the intron 20 and 3 of FGFR2 and PPHLN1, respectively. Schematic
representation of the sequence around the breakpoint is here reported.
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Figure 2 | Incidence of FGFR2–PPHLN1 and FISH validation. (a) FISH conﬁrmed the co-localization of FGFR2 and PPHLN1 probes in the tumour of the case
where it was identiﬁed but not in its normal tissue [upper panel: (left) representative image of the non-tumoral tissue ICC23, arrows indicate normal,
fusion-negative alleles; (right) representative image of the tumoral tissue ICC24 positive for the FGFR2 rearrangement. White arrows indicate the FGFR2–
PPHLN1 translocation]. To determine the incidence of this fusion event in iCCAs, we screened a cohort of 107 FFPE tumours. FISH was used to conﬁrm the
presence of DNA rearrangement in 10 FFPE cases (four positive and six negative) previously screened by RT–PCR and Sanger sequencing [lower panel:
(left) representative FISH image of a negative patient; (right) representative FISH detection of FGFR2–PPHLN1 in a positive patient; white arrows indicate the
translocation]. Results were concordant in all but one case where the patient was called positive by FISH but not by RT–PCR screening revealing 90%
concordance between the two techniques. This discrepancy might suggest a higher sensitivity of FISH over RT–PCR in this particular case probably due to
the high texture admixture observed in this sample. (b) RT–PCR and subsequent Sanger sequencing identiﬁed the exact fusion breakpoint in 16% of
patients (17/107). Sanger sequencing of six representative patients is shown herein.
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Also normal FGFR2 and PPHLN1 protein are represented. (b) Soft agar assay for colony formation was performed with NIH3T3 cells stably transfected with
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FGFR2–PPHLN1 grown with or without BGJ398. NIH3T3 cells transfected with empty vector are also indicated. Graph represents the mean±s.d. of cell
counts for three separate wells of three independent experiments (meanþ s.d.).
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KRAS signalling pathway in the tumours harbouring the FGFR2
fusions (Po0.001, Student’s t-test, Fig. 4c). When we performed
classic GSEA comparing the patients with FGFR2 fusions versus
the rest, KRAS pathways were found among the top enriched
ones (Po0.05, false discovery rate (FDR)o0.05, Kolmogorov–
Smirnov statistic test). Consistently, 90% of the patients
harbouring KRAS mutations were also positive for FGFR2
fusions, suggesting cooperation between these two pathways
(Fig. 4c, P¼ 0.01, Fisher’s exact test).
FGFR2 is located within the Aphidicolin-inducible fragile site
FRA10F on chr10q26.1 (ref. 23). Several DNA-damage response
proteins have been shown to regulate the stability of fragile
sites24,25, including Ataxia telangiectasia mutated (ATM) and
Rad3 related (ATR) and its effector Chk1 (ref. 26). Interestingly,
ATM pathway genes were found to be signiﬁcantly down-
regulated in patients harbouring FGFR2 fusions as revealed by
ssGSEA (Fig. 4c, Po0.03, Fisher’s exact test) and by classic GSEA
(Po0.05, FDRo0.05, Kolmogorov–Smirnov statistic test). These
observations imply that FGFR2 rearrangements represent the
most recurrent molecular alteration event reported so far in
iCCA. Furthermore, frequent co-occurrence of KRAS mutations
and FGFR2 fusion events suggests a possible cooperative role in
driving iCCA pathogenesis, whereas the deregulation of pathways
involved in the stability of fragile sites may be responsible for the
occurrence of such rearrangements.
Exome sequencing identiﬁes novel ARAF mutations. We
explored exome sequencing (exome-seq) data generated on eight
pairs of iCCA tumour and paired non-tumour tissues (seven
equal cases as above). We identiﬁed 237 alterations in the coding
regions including 229 mutations affecting 209 genes (range 18–
53, average 30 per tumour) and eight insertions and deletions
(indels; Supplementary Fig. 4, Supplementary Table 5). Somatic
substitutions were predominantly C:G4T:A transitions as pre-
viously reported in iCCA and other cancers7–11. Of the mutations
identiﬁed, 64% were missense, 28% were silent, 5% were nonsense
and 3% were indels (Fig. 5a). Globally, 199 genes were mutated in
only one patient, nine genes were mutated in two patients
(Supplementary Table 6) and 13 genes presented more than one
mutation (Supplementary Table 7). Among the 163 non-
synonymous mutations identiﬁed, 75 were predicted to have
damaging functional consequences by using the Polyphen-2
algorithm (range 5–17, average 9 per sample, Supplementary
Table 8), including a novel truncating mutation in ARID1A and
two missense mutations in the ARAF gene, G322S, a novel
mutation in the kinase domain and N217I, which has been
previously reported7 (Supplementary Fig. 5a). ARAF mutations
were conﬁrmed by independent PCR and sequencing in each
tumour. External validation of the identiﬁed ARAF mutations
along with the screening of the entire kinase domain (exons 10–
16) of the gene revealed the presence of 11 different mutations in
nine patients out of 84 (11%; Fig. 5b, Supplementary Table 9).
The novel mutations included two nonsense and nine missense
mutations (Supplementary Table 9). All missense mutations were
predicted to be damaging by Polyphen-2. To investigate whether
these mutations were somatic, the surrounding non-tumoral
tissue and nine non-neoplastic liver tissues were analysed by PCR
and Sanger sequencing (Supplementary Figs 6–8). In three
patients, the non-surrounding tissue was available and the
analysis conﬁrmed that the four identiﬁed mutations (A541V,
G322S, S469F and W472*) were indeed bona ﬁde somatic
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Figure 4 | FGFR2 fusions represent a potential therapeutic target. (a) HUCCT1 cell line transfected to overexpress FGFR2–PPHLN1 showed an increased
sensitivity to BGJ398 (5 mM) compared to its parental cell line transfected with the empty vector (Po0.001, Student’s t-test). Reading was performed after
72 h incubation with BGJ398. Results were normalized to dimethylsulphoxide (DMSO)-treated controls and presented as the mean of three independent
experiments (meanþ s.d.). (b) BGJ398 (1 mM) was able to reduce cell migration only in HUCCT1 cell line expressing FGFR2–PPHLN1 (Po0.0001, Student’s
t-test). (c) A validation cohort of 107 iCCAs was screened for the presence of FGFR2 fusions. FGFR2–PPHLN1 and the previously reported FGFR2–BICC1 were
present in 16% and 38% of iCCA cases, respectively, and were not mutually exclusive. Presence of FGFR2 rearrangements was also investigated in 21 mixed
HCC–iCCA tumours (here shown) and 100 HCCs. Only one mixed HCC–iCCA tumour belonging to the histological subtype of stem cell features was found
positive for FGFR2–BICC1. No FGFR2 fusion was identiﬁed in any of the HCC samples analysed. Signiﬁcant association was found between presence of FGFR2
fusion and KRAS pathway activation in breast and lung (Po0.001, Student’s t-test) and/or KRAS activating mutation (P¼0.01, Fisher’s exact test).
Signiﬁcant ATM target downregulation was observed in patients harbouring FGFR2 rearrangements. Enrichment scores for each sample were calculated by
ssGSEA and is displayed here as a heatmap.
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(Supplementary Figs 6,7). In addition, none of the nine normal
livers analysed carried the mutations, thus suggesting that these
mutations are more likely to represent somatic events. To verify
the impact of the most frequent mutations on the activity of the
protein, we overexpressed WT ARAF and N217I and G322S
mutant variants in CCA cell lines (TFK-1 and HUCCT1).
Western blot analysis showed increased phosphorylation of the
downstream molecule MEK in cells overexpressing the N217I and
G322S mutants compared with empty vector and ARAF WT
(Fig. 5c). Furthermore, the cell lines expressing the N217I ARAF
mutant showed increased viability compared with the parental
cell line, whereas G322S mutant had no effect or slightly slowed
cellular viability (Fig. 5d, Supplementary Fig. 5b). N217I and
G322S mutations were not able to transform NIH3T3 in vitro
suggesting that further studies need to be conducted to clarify the
potential oncogenic role of these mutations in iCCA. Of note, we
have demonstrated that ARAF mutations G322S and N217I
are able to induce the constitutive activation of the down-
stream pathway and N217I might possess oncogenic activity
in vitro. Furthermore, our screening identiﬁed novel damaging
mutations in the ARAF oncogene, which occur in 11% of the
iCCA patients.
Integrative analysis unveils speciﬁc iCCA subgroups. To pro-
vide an overview of the genomic landscape of molecular altera-
tions in iCCA, we integrated exome- and RNA-seq data with our
previously published iCCA molecular classiﬁcation5. IDH1 and
IDH2 mutations were observed in 11 (11/107, 10%) and 7
patients, respectively (7/107, 7%, Supplementary Table 10).
Interestingly, patients with IDH1 and IDH2 mutations were
signiﬁcantly enriched in P2–P3 subgroups of our proliferation
subclass (15/45 versus 3/62 rest, Po0.001, Fisher’s exact test,
Fig. 6), which is associated with chromosomal instability,
enrichment of a stem cell-like iCCA signature27 and activation
of EGFR signalling. Consistent with the functions of IDH1/2
enzymes, the pathways related to tricarboxylic acid cycle and
electron transport were enriched in patients with IDH mutations
(FDRo0.05, Supplementary Table 11). Moreover, a recently
published iCCA signature with stem cell-like features27 was
signiﬁcantly enriched in IDH mutant tumours28 along with
several oncogenic pathways including KRAS, MET, NOTCH and
VEGF pathways.
iCCA tumours harbouring the FGFR2 fusions did not show
signiﬁcant enrichment in any of the iCCA subclasses (Fig. 6). As
above described, there was a signiﬁcant association between the
presence of FGFR2 fusions and KRAS activating mutations
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(P¼ 0.01, Fisher’s exact test). No signiﬁcant association was
found with other mutations analysed such as ARAF (11%), BRAF
(4%), IDH1/2 (17%), EGFR (2%) and high-level ampliﬁcation at
11q13 (4%) (Fig. 6)5. Overall, 69% (79/114) of iCCA patients
harboured at least one targetable molecular alteration (Fig. 6) and
more likely may respond to targeted molecular therapies
highlighting the relevance of translating these ﬁndings to
clinical settings.
Discussion
iCCA is an orphan disease for which there is currently no ﬁrst-
line approved standard of care for unresectable cases2. Here we
provide compelling evidence indicating that FGFR2 fusions,
including the novel FGFR2–PPHLN1 fusion, are highly frequent
molecular aberrations in iCCA (B45%) and might represent a
therapeutic opportunity. In addition to the detection of these
fusion events, we describe previously unknown damaging
mutations in the ARAF oncogene (11%) and deﬁne a complete
landscape of targetable mutations in this cancer (for example,
IDH1/2, BRAF, KRAS, EGFR) occurring in at least 70% of
patients.
The identiﬁcation of the EML4–ALK fusion in a small
subgroup of patients with lung cancer has provided the rationale
for demonstrating survival beneﬁts for speciﬁc molecular
therapies, such as crizotinib16. The short time frame elapsed
between the discovery of the fusion14, the conduction of a proof-
of-concept trial29 and the ﬁnal demonstration of survival beneﬁts,
have opened a new paradigm for translating oncodriver
discoveries into clinical practice. Our current study provides a
comprehensive landscape of molecular alterations occurring in
iCCA and unveils a surprising high prevalence of FGFR2 fusions,
which are therefore expected to have clinical impact as
therapeutic targets. Our functional analysis demonstrated that
the newly identiﬁed FGFR2–PPHLN1 fusion possesses
transforming and oncogenic capability and can be effectively
targeted by a small-molecule FGFR2 inhibitor.
In our study, FGFR2 fusions were found in 45% of iCCA
patients, in 5% of HCC–iCCA mixed tumours and were absent in
HCC. These data are consistent with recent reports where FGFR2
fusions were reported in iCCA (9/66, 14%) but rarely in HCC
(1/98) (ref. 19). Nonetheless, the incidence of FGFR2 fusions
strikingly differs across the iCCA published cohorts, with a range
between 50% in small series17,18 to 10–15% in series of up to 96
patients19,20,30. Overall, our cohort consisted of Caucasian
patients at early-intermediate stage iCCA amenable for
resection, whereas other series mostly refer to Asian patients at
more advanced stage of disease19. In our study, no differences in
terms of gender, age, viral infection, stage and prognosis was
observed between patients harbouring or not FGFR2 fusions. In a
Japanese study, there was a signiﬁcant association between
patients with viral infections and FGFR fusions, a fact not
observed in our cohort19. Thus, while we cannot conclude from
these data whether viral infections or underlying liver disease
might contribute to the occurrence of FGFR2 translocations in
iCCA patients, we could speculate that different ethnicity and
geographical population might partially explain such discrepancy.
Ad hoc larger studies need to be conducted to clarify such
discrepancies.
In addition, we observed that FGFR2 fusions were not mutually
exclusive with each other, with 10% of the iCCA patients showing
presence of both FGFR2–PPHLN1 and FGFR2–BICC1 fusion
genes. There are several potential explanations for the speciﬁc
presence of FGFR2 fusions in iCCA and the co-occurrence of
multiple types of FGFR2 fusions in the same tumour, although it
needs to be determined whether the different fusions co-exist in
the same iCCA cell or represent different iCCA cells in single cell-
level analysis. The presence of fragile sites and/or hot spots for
genomic DNA rearrangements within the FGFR2 gene, for
example, FRA10F (ref. 23), may explain this phenomenon. Recent
studies have revealed that the presence of AT-rich sequences in
the region can form highly stable secondary structures promoting
DNA breakage24,25. Of note, the ATM pathway—involved in the
regulation of fragile sites26—was found to be signiﬁcantly down-
regulated in our patients harbouring FGFR2 rearrangements,
suggesting this pathway may play an important role in the
occurrence of these fusion events in iCCA.
We also provided evidence that a FISH-based assay can be used
as a biomarker that correlates with the presence of the discovered
fusion. To date, no mutations or focal ampliﬁcations have been
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described for FGFR2 and the reported fusions17–20 appear to be
the main mechanism of activation of this oncogene and could be
explored for trial enrichment. For example, early clinical trials
exploring the concept of potential oncogenic addiction to FGFR2
could be enriched by iCCA patients with positive FGFR2 fusions
detected by FISH. Nonetheless, although tumour tissue-based
FISH is a clinically applicable measure to detect the presence of
FGFR2 fusions18,19,30, their detection in plasma or serum may
enable less invasive and more ﬂexible screening strategies that
potentially provide indication for FGFR2 inhibitors in treating
advanced-stage iCCAs. In this sense, studies correlating liquid
biopsy ﬁndings with iCCA tissue FGFR2 fusions are expected.
FGFR2 fusions were not mutually exclusive with the presence
of other mutations. Activating mutations of KRAS are frequent
molecular alterations in iCCA (22%, range 5–57%)4, as also seen
in our study (10%). Interestingly, KRAS mutation-positive
tumours also harbour the FGFR2 fusions (90%), suggesting
their cooperative role in driving iCCA pathogenesis. This
association was not observed in a previous genomic study of
iCCA19 and thus the ﬁnding needs to be further conﬁrmed.
A handful of mutations identiﬁed so far in iCCA can be
potentially targeted by speciﬁc drugs. Novel mutations in
chromatin remodelling genes (for example, ARID1A, BAP1 and
PBMR1) have emerged and account for the most frequent
mutations reported so far in iCCA (B25%)8,9 as it has also been
corroborated in recent studies where mutations in such genes
have been identiﬁed even at higher frequency (34–46%)10,20. At
the same time, already described mutations (for example, KRAS,
IDH1/2, and EGFR) have been conﬁrmed7–11,20. Notably, IDH1/
2-activating mutations occur in B20% of the iCCA cases4—17%
in our series—and tend to be mutually exclusive with other
mutations. Phase I trials with speciﬁc inhibitor of IDH1/2
mutations are currently ongoing in cholangiocarcinoma patients.
In the current study, by applying exome-seq and screening of a
large cohort, we conﬁrmed some known mutations (for example,
ARID1A, IDH1/2) and identiﬁed two activating mutations and 10
potentially damaging mutations in ARAF, a member of the RAF
oncoproteins. ARAF is a serine–threonine-speciﬁc protein kinase
that activates the MEK/ERK signalling cascade downstream of
RAS (ref. 31). ARAF mutations are rare compared to BRAF and
CRAF (ref. 32). In this study, we identiﬁed two mutations in
ARAF: N217I, which had been previously reported in iCCA7 and
G322S, a novel mutation in the kinase domain. ARAF shows 90%
homology with the other 2 RAF genes of the family and share
three highly conserved regions (CR1–CR3)33. CR1, at the N
terminus, is composed of a RAS-binding domain. CR2 is a
regulatory region with a serine/threonine-rich domain and is
followed by the protein kinase domain (CR3) near the C
terminus. The ability of RAF proteins to bind to RAS is
regulated by several adaptor and scaffold signalling proteins,
such as 14-3-3 proteins. The N217I mutation is located in the
regulatory region close to one of the known sites of
phosphorylation and 14-3-3 binding (S214). Substitution of
serine 214 by alanine (S214A) leads to an increased basal and
inducible ARAF kinase activity when compared to the WT
enzyme34. Similar results were also obtained with the homologous
serine in BRAF (S365) indicating that the phosphorylation of this
site and its interaction with 14-3-3 protein acts as a negative
regulator of RAF activity35. The domain where G322S is located is
highly conserved across all the three genes and the corresponding
mutation in BRAF has been demonstrated to be activating36. Here
we demonstrated that the mutations N217I and G322s are able to
increase the phosphorylation of the downstream effectors and
N217I might possess oncogenic activity in vitro. Screening of our
prevalence cohort for these two mutations along with the
evaluation of the kinase domain revealed that overall 11% of
the iCCA population harbours mutations in ARAF gene. These
mutations are novel7–10,20, and their oncogenic potential needs to
be properly investigated in experimental models.
In conclusion, we have shown that FGFR2 fusions are the most
recurrent targetable molecular alteration described so far in iCCA
(B50%), including the novel FGFR2–PPHLN1 fusion unveiled
here by RNA-seq in 16% of the patients analysed. In addition, we
identiﬁed novel mutations in the oncogene ARAF, which might
represent a novel potential target, and warrants further clinical
evaluation.
Methods
Tumour samples and nucleic acid extraction. Fresh frozen tumour tissues and
corresponding normal tissue (n¼ 7 pairs) from resected iCCA patients were col-
lected from the Biorepository Tissue Bank at the Icahn School of Medicine at
Mount Sinai (New York) after approval by the institutional review board (IRB)
committee. Informed consent was obtained for all the subjects. The samples
chosen contained only tumoral tissue and were free of non-tumoral liver par-
enchyma. Furthermore, the diagnosis of iCCA was conﬁrmed by an expert liver
pathologist. Total RNA was extracted from homogenized iCCA samples and their
normal conterparts using TRizol Regent (Invitrogen). Quantity of RNA was
measured using Quant-iT Ribogreen RNA assay kit. One mg of RNA was used for
subsequent RNA-seq library generation. DNA was isolated using the ChargeSwitch
gDNA Mini Tissue Ki/t (Invitrogen) after tissue disruption with a homogenizer.
DNA quantity was assessed through Quant-It PicoGreen dsDNA Assay kit
(Invitrogen).
A total of 107 formalin-ﬁxed, parafﬁn-embedded (FFPE) samples were obtained
from iCCA patients resected between 1995 and 2007 at three centres from the HCC
Genomic Consortium: IRCCS Istituto Nazionale Tumori (Milan), Mount Sinai
School of Medicine (New York) and Hospital Clinic (Barcelona). The study
protocol was approved at each center’s IRB. The iCCA samples used represent a
subgroup of a larger cohort (n¼ 149) previously published elsewhere5. Gene
expression data of these samples has been deposited in the GEO database
(GSE33327), whereas description of the entire cohort is available in Table 1 of ref.
5. Description of the samples used in the current study is summarized in
Supplementary Table 4. Clinicopathological characteristics and follow-up data were
available for 98/107 patients analysed for FGFR2 fusions (see details in
Supplementary Table 4).
A total of 21 FFPE mixed HCC–iCCA tumours were collected at the Icahn
school of Medicine at Mount Sinai (New York, NY) after approval by the IRB
committee. According to the WHO Classiﬁcation 2010 (ref. 37), four cases belong
to the classical type with areas of typical HCC and areas of typical CCA, whereas 17
cases belong to the stem cell type. Furthermore, 6/17 stem cell type tumours were
categorized as cholangiolocellular subtype. All the tissue sections were
macrodissected to avoid contamination of non-cancerous liver tissue on RNA
extraction. In brief, for each classical type, the HCC part was separated from the
iCCA component. Surrounding non-tumoral tissue was also extracted. For the
stem cell features types, tumour was separated from the surrounding tissue but,
considering the complexity of this subtype and the lack of speciﬁc markers, no
further microdissection was performed for the purpose of the current study. All the
different areas macrodissected were screened for the presence of FGFR2
rearrangements. Total RNA was isolated from three freshly cut 5-mm-thick FFPE
sections using QIAcube (QIagen, Du¨sseldorf, Germany)5. RNA quantity was
assessed using Quant-iT Ribogreen RNA assay kit (Invitrogen). A total of 100
surgically resected fresh frozen HCC samples were obtained from two institutions
of the HCC Genomic Consortium: IRCCS Istituto Nazionale Tumori (Milan, Italy)
and Hospital Clı´nic (Barcelona, Spain) after approval by the IRB committee. Tissue
was pulverized using the BioPulverizor (Biospec, Bartlesville, OK) to ensure a
homogenous mix of cells and stored at  80 C. RNA was extracted using the
RNeasy mini kit (Qiagen, Germantown, MD).
RNA-seq technology and fusion gene identiﬁcation. The sequencing library was
prepared with the standard TruSeq RNA Sample Prep Kit v2 protocol (Illumina,
CA, USA). In brief, total RNA was poly-A-selected and then fragmented. The
cDNA was synthesized using random hexamers, end-repaired and ligated with
appropriate adaptors for sequencing. The library then underwent size selection and
puriﬁcation using AMPure XP beads (Beckman Coulter, CA, USA). The appro-
priate Illumina recommended 6-bp bar-code bases are introduced at one end of the
adaptors during PCR ampliﬁcation step. The size and concentration of the RNA-
seq libraries was measured by Bioanalyzer and Qubit ﬂuorometry (Life Technol-
ogies, USA) before loading onto the sequencer. The mRNA libraries were
sequenced on the Illumina HiSeq 2500 System with 100 nucleotide single-end
reads, according to the standard manufacturer’s protocol (Illumina, USA).
Between 20 and 25 million 100-bp reads were generated for each of the seven
matched normal samples. Actual alignment of the raw cDNA reads was carried out
by tophat-fusion38 and de novo assembly of transcript level reads was carried out
by Cufﬂinks39,40. In brief, tophat-fusion breaks up individual reads into 25-bp
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segments, which are mapped independently to the reference build hg19
via bowtie41. Following Edgren et al.42, we used the following ﬁltration scheme to
identify fusion events: (1) BLAST sequence around putative breakpoint to hg19
build to identify and remove paralogous sequences; (2) ﬁlter fusions based on the
number of reads that support the putative fusion breakpoints, setting the minimum
number of such spanning reads conservatively; (3) compute scores of distributions
of coverage of reads around the putative breakpoints, rejecting non uniformly
covered reads; (4) fusions between adjacent genes were rejected as read-through
transcript events, with a minimum distance of 100 kb; (5) ﬁnally, we considered a
read to support a fusion if it mapped to both sides of breakpoint by at least a
minimum fusion anchor length of 25 bp, or generally about a quarter of a read
length. All these parameters were essentially tuned with the constraint that the
matched normal sample had no positive fusion detections. RNA-seq data of these
samples has been deposited in the GEO database (GSE63420).
Whole-exome sequencing and somatic mutation detection. Genomic DNA was
sheared using the Covaris E210 system (Covaris, Woburn, MA). Total genomic
DNA library is generated following the manufacturer protocol (NEBNext DNA
Library Prep Master Mix Set for Illumina, New England Biolabs, Ipswich, MA). At
this point, the library is ready for WGS. For whole-exome sequencing, the WGS
library then undergoes solution-based hybridization to an oligonucleotide pool
designed to enrich for the whole-exome regions of interests. The library is captured
by following the manufacturer protocol (SeqCap EZ Human Exome Library v3.0
User Guide, Roche NimbleGen, Madison, WI).
Eight normal iCCA pairs (including the seven reported above) underwent
whole-exome sequencing and one normal iCCA pair underwent WGS. The
experiments achieved high quality in the metrics of high read quality, high
mapping rate, low duplication rate and adequate coverage of the target regions.
PCR and optical duplicates, low-quality (Qo20) and non-uniquely mapped reads
were successfully removed. Remaining reads were aligned to the human genome
reference 19th version using BWA43. Afterwards, somatic single-nucleotide
variants and small indels were identiﬁed through VarScan2 (ref. 44). We calculated
the P value using Fisher’s exact test for all putative mutation sites based on the
distribution of read support for different alleles in tumour and matched normal
samples. The VarScan2 software was employed in above analyses because of their
desirable feature in detecting mutations in low purity or heterogeneous cancer
samples. Purity information was factored in mutant allele frequency estimations.
Structure variants were identiﬁed on WGS data, using CREST software (PMID:
21666668).
Somatic single-nucleotide variants and indels inferred by VarScan2 software
were ﬁltered based on the following criteria: (1) Read depth Z20 in both tumour
and normal samples; (2) read support of mutant allele in tumour tissue not a
result of a sequencing error (binomial test, P40.01); (3) quality score not
signiﬁcantly lower than other alleles (Wilcoxon rank-sum test, P40.01). (4)
Mutant allele frequency change between tumour and adjacent normal Z20% and
Fisher’s exact test P value o0.01; (5) mutant allele not signiﬁcantly enriched in
repeatedly aligned reads; (6) mutant allele not signiﬁcantly enriched within 10 bp of
50 or 30 ends of reads (Fisher’s exact test, P40.01); (7) mutant alleles were observed
in both forward and reverse strand of the tumor DNA; ﬁnally, the resulting
mutations were annotated by the SNPEff pipeline, in terms of mutation location,
impact on gene product and the likelihood of the mutation to be functional (SIFT
and PolyPhen-2 scores). Structural variants were ﬁltered based on the following
criteria: (1) the breaking point site read depth Z20; (2) at least observe ﬁve
soft-clip reads; and (3) read supports observed in both strand. In brief, high-quality
sequences based on low duplication rate (range 7–18%), high mapping rate
(range 96 millions  158 millions reads; average 127 millions reads) and adequate
coverage were achieved. Exome-seq data has been deposited in the GEO
database (GSE63420).
cDNA conversion and RT–PCR reaction. One microgram of RNA was retro-
transcribed into cDNA using the RNA to cDNA Ecodry Premix (Clontech) fol-
lowing manufacturer’s instructions. The resulting cDNA was used as template for
semiquantitative PCR ampliﬁcation using the primers reported in Supplementary
Table 11. To detect the presence of the fusion product, the PCR ampliﬁcations on
human tissues were performed using the following protocol: 95 C for 2min, 40
cycles of 95 C for 30 s, 55 C for 30 s, 72 C for 2min. PCR ampliﬁcations were
performed in a volume of 25ml reaction mixture containing 1.5mM MgCl2,
0.2mM of each dNTP, 0.125mM of each primer and 1U of Platinum Taq DNA
polymerase (Invitrogen). PCR products were puriﬁed using the Qiaquick PCR
puriﬁcation kit (Qiagen) and sequenced using an Applied Biosystems 3700 DNA
sequencer (ABI PRISM 3730XL; Applied Biosystems). The cases analysed by PCR
were considered positive only if Sanger sequencing successfully conﬁrmed the
sequence of the fusion mRNA around the breakpoint.
For the ampliﬁcation and subsequent cloning of the full fusion gene, 1 mg of
RNA of the index case was reverse transcribed using 2 pmol of the gene speciﬁc
reverse primer with Superscript III (Invitrogen) following manufacturer’s
instructions with the exception that 1 h incubation was at 55 C. 2 units of RNase H
(NEB) was added to the reaction to remove complementary RNA and incubated at
37 C for 20 min.
Fluorescent in situ hybridization. Commercially available satellite probes
(FGFR2-RP11-62L18-orange 5-TAMRA dUTP and PPHLN1-RP11-154F20 5-
Fluorescein dUTP) mapping to the corresponding regions of chr10:123,224,100-
123,398,498 and chr12:42,694,068-42,878,307 respectively, were purchased from
Empire Genomics LLC (Buffalo, NY). Four-micrometer sections from FFPE iCCA
tissues were baked at 60 C for at least 2 h and then deparafﬁnized and rinsed
through water. The slides were incubated in a sodium thiocyanate solution (16 g
sodium thiocyanate per 200ml puriﬁed water) for 10min at 80 C and then washed
in PBS. They were then incubated in 0.2% pepsin in 0.01N HCl for 20min at 37 C
followed by quenching in 2xPBS plus glycine. Slides were then postﬁxed in 4%
paraformaldehyde then washed in PBS three times over 15min and ﬁnally dehy-
drated. Previously denatured probes were added onto slides, which were then
coverslipped and placed in a HYBrite chamber (Vysis, Abbott Molecular, Abbott
Park, IL) where they were denatured for 3min at 83 C and hybridized overnight at
37 C. Slides were washed in 50% Formamide in 1 saline sodium citrate three
times for 5min at 37 C, followed by three 5min 1 saline sodium citrate and
three 0.1% Tween-20 4 SCC washings at 37 C. Slides were dehydrated and
counterstained with mounting medium with DAPI (40,6-diamidino-2-pheny-
lindole,Vector Laboratories Inc., Burlingame, CA). Results of the hybridization
were visualized with an automated Leica DM5500B ﬂuorescence microscope and
scored using the Leica Application Suite Advanced Fluorescence LAS AF software
(Leica Microsystems Inc., Buffalo Gove, IL) following the next criteria: for each
case, microphotographs of 10 microscopic high power ﬁelds ( 1,000, oil
immersion) corresponding to iCCA tumour areas were obtained with DAPI,
ﬂuorescein isothiocyanate and Cy3 ﬁlters. Numbers of green and orange signals
were counted for each DAPI-labelled nucleus (100 nuclei were scored for each
sample). Presence of fusion was determined when the signals from the two probes
(FGFR2 in red and PPHLN1 in green) were overlapping and a yellow signal was
observed. Individual images of representative fusion-positive and fusion-negative
iCCA cases were captured with a Zeiss Axio Imager Z2 microscope (Zeiss, Jena,
Germany) with the same set of ﬁlters described above, using the CytoVision 7.2
software (Leica Microsystems Inc., Buffalo Gove, IL).
Microarray data. Gene expression data for the independent cohort (n¼ 107) were
already available (Microarray GEO number: GSE33327)ref. 5). Genes, molecular
pathways and gene expression signatures associated with the classes were evaluated
using GSEA for Molecular Signature Database gene sets (MSigDB,
www.broadinstitute.org/msigdb). Data analysis was conducted using the
GenePattern Analytical Toolkit, whereas the correlation with clinicopathological
parameters was performed with SPSS software (version 18). Correlation between
the presence of FGFR2 fusions and clinicopathological variables was assessed by
Fisher’s exact test.
Cell lines and FGFR2 inhibitor. HUCCT1 (Riken Bioresource Center, Ibaraki,
Japan) and TFK-1 (DSMZ) were maintained in RPMI supplemented with 10%
heat-inactivated fetal bovine serum. Cells (293T) were grown in Dulbecco’s
modiﬁed Eagle’s medium with 10% heat-inactivated fetal bovine serum. Cells were
maintained at 37 C in a 5% CO2 atmosphere. The FGFR2 inhibitor, BGJ398, was
purchased from SelleckBio (http://www.selleckbio.com) and added at the cell cul-
ture at different concentrations (range 100 nM–10 mM).
Cloning strategy and stable transfection. The fusion FGFR2–PPHLN1 cDNA
was ampliﬁed by PCR using the Pfx platinum system from Invitrogen and the
primers reported in Supplementary Table 12; 5 ml template was added to the
reaction. The PCR ampliﬁcations were performed using the following protocol:
95 C for 2min, 45 cycles of 95 C for 1min, 52 C for 1min and 72 C for 5mins.
A secondary PCR was performed on 2 ml of primary PCR using primers designed
with an attB overhang to amplify the fusion cDNA in frame for cloning into the
Gateway system for mammalian expression (Invitrogen; primers sequence is
reported in Supplementary Table 12). The attB PCR product was cloned ﬁrst into
pDONR-zeo to create an entry clone and then shuttled into the mammalian
expression vector pcDNA 6.2Em/GFPBsd/V5-DEST according to manufacturer’s
instructions to create pDEST-V5-FGFR2/PPHLN1. Cloning reactions were incu-
bated overnight to achieve maximum recombination efﬁciency. Constructs were
conﬁrmed by Sanger sequencing. Expression constructs (pReceiver-M12 vector,
OmicsLinkTM) containing WT human ARAF ORF (NM_001654.4) and mutation
variants (N217I and G322S) were purchased from GeneCopoeiaTM (Rockville,
USA). Six-well plates containing 2 105 HUCCT1 and TFK-1 cells were stably
transfected with 2.5 mg linearized vectors using the Lipofectamine transfection
system (Invitrogen) or X-treme gene DNA HP transfection reagent. Following 48 h
of transfection, cells were selected with Blasticidin (10 mgml 1) or Geneticin
(500 mgml 1, G418 disulfate salt, Sigma).
Validation of ARAF mutations and IDH mutations screening. Validation of the
two ARAF mutations identiﬁed by exome-seq and screening of the kinase domain
PCR was performed using speciﬁc primers (Supplementary Table 12). Each PCR
reaction contained 1 Platinum Taq DNA Polymerase Buffer (Invitrogen),
0.2mM dNTPs mix, 1.5mM MgCl2, 0.2 mM of each primer and 100 ng of gDNA.
The following PCR reaction conditions were used: 95 C for 2min, 35 cycles of
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95 C denaturation for 30 s, 59 C annealing for 30 s and 72 C extension for 30 s,
followed by a 5-min ﬁnal extension at 72 C. Matched non-tumoral surrounding
tissues and in nine non-neoplastic liver tissues obtained from patients who
underwent resection due to non-malignant liver conditions were analysed for the
mutations. For IDH1/2 mutations screening, the PCR ampliﬁcations were per-
formed in a volume of 25ml reaction mixture containing 1.5mM MgCl2, 0.2mM of
each dNTP, 0.125mM of each primer and 1U of Platinum Taq DNA Polymerase
(Invitrogen). PCR products were puriﬁed using the Qiaquick PCR puriﬁcation kit
(Qiagen) and sequenced using an Applied Biosystems 3700 DNA sequencer (ABI
PRISM 3730XL; Applied Biosystems).
Immunoprecipitation and western blot analysis. Proteins were extracted with
RIPA buffer containing phosphatase (78428, ThermoScientiﬁc, Maltham, MA) and
protease inhibitors (04693124001, Roche, Basel, Switzerland). Cell extracts were
prepared from cells transiently or stably transfected with the mammalian expres-
sion empty vector or pDEST-V5-FGR2/PPHLN. The lysate (300 mg) was immu-
noprecipitated with anti-V5 antibody (1/250 dilution, cat#R960-25, Life
Technology) for 3 h at 4C. Lysates were incubated with protein A/G Agarose beads
(cat# 20423, Pierce) for 1 h at 4C. After the washing steps, beads were resuspended
in Laemmli sample buffer. Immunoprecipitated V5-FGFR2–PPHLN1 fusion pro-
tein was detected by western blot using the anti-V5 antibody (1/1,000). Results
were conﬁrmed by using the anti-FGFR2 antibody (ab75984, Abcam, 1/1,000).
Activation of V5-FGFR2–PPHLN1 was detected by western blot using the anti-
phosphotyrosine clone 4G10 antibody (cat# 05-321, Millipore, 1/1,000).
Thirty mg of proteins was loaded on 7.5–10% SDS gels and transferred to
polyvinylidene diﬂuoride membranes. Membranes were bovine serum albumin
blocked and hybridized at 4 C overnight with primary antibodies. Horseradish
peroxidase-conjugated secondary antibody was applied at room temperature for
1 h. Blots were developed using RPN 2132 ECL plus solution (GE Healthcare) and
imaged with FUJIﬁlm Laser Image Analyzer (GE Healthcare Life Sciences,
Waukesha, WI). Antibodies against total ERK (#4695), MEK1/2 (#9122), ARAF
(#4432) BRAF (#9433) phospho-ERK1/2(Thr202/Tyr204), (#9101), phosho-
MEK1/2 (Ser217/Ser221) (#9121) were from Cell Signaling (Danvers, MA) and
were used 1:2,000. Antibody against a-tubulin (T-5168) was from Sigma-Aldrich
(St Louis, MO) and was used 1:2,000. Uncropped images have been provided and
can be found in Supplementary Fig. 9.
Transforming activity of FGFR2–PPHLN1 and ARAF mutations. Mouse NIH3T3
ﬁbroblast cells were transfected with empty vector, FGFR2–PPHLN1, ARAF WT,
ARAF N217I, ARAF G322S. Colonies count was performed on day 21 using an
inverted microscope. NIH3T3 cells transfected with FGFR2–PPHLN1 were cul-
tured in the presence or absence of the FGFR inhibitor BGJ398 (1 mM). The
compound solution was added to the top layer of soft agar every 3 days.
In vitro functional assays. Cells stably transfected with empty vector and
destination vectors (3,000 per well) were plated in 96-well plates in triplicate. Cell
proliferation was monitored after 24, 48 and 72h using colorimetric 3-(4,5-dime-
thylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-(4-sulfophenyl)-2H-tetrazolium
assays (MTS; Promega) according to the manufacturer’s instructions. Optical den-
sities were measured with a Biotek plate reader. Migration assay was performed
using Transwell chambers (8-mmol l 1 pore size; BD Bioscience, Bedford, MA). In
brief, 20,000 cells were resuspended in 250 ml of serum-free medium and plated in
the upper chamber. Medium (650ml) containing 5% fetal bovine serum was added to
the lower chamber. Cells were incubated at 37 C forB24 h. After culture, cells that
migrated from the upper well of a transwell chamber into the lower well were stained
with crystal violet and counted45. For the clonogenic assay, cells were plated at low
density (100 per well) in six-well plates in triplicates. Medium was changed twice per
week. After 2 weeks, colonies were stained with crystal violet for 30min and counted
under a light microscope. The results are normalized to the control and presented as
the mean of three independent experiments (meanþ s.d.). Statistical signiﬁcance
was analysed by two-sided paired t-test.
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